Pharmaceutical CMO Market Share

Market Share of Pharmaceutical CMO Industry

The market studied is highly fragmented, with major vendors accounting for most of the market share. The presence of many players in the market impacts the pricing of services, making it a direct competing factor, especially for small-scale vendors. The vendors in the market studied are expected to focus on providing one-stop-shop services, providing them with a competitive advantage. These practices would be possible for CMOs with access to large capital. This factor increases the competition and creates a new players' entry barrier. Some of the major players in the market are Patheon Inc. (Thermo Fisher Scientific Inc.), Lonza Group, Catalant Inc., Pfizer CentreOne (Pfizer Inc.), and Boehringer Ingelheim Group.

• February 2024: Catalent Inc. and Novo Holdings announced that they had entered into a merger contract under which Novo Holdings acquired Catalent for USD 16.5 billion in all-cash transactions. The acquisition of Catalent is aligned with Novo Holding's order to invest in high-quality life sciences companies to benefit the Novo Nordisk Foundation's mission and philanthropic causes.
• December 2023: Advanced and Emerging Therapeutic Business Unit of ReciBioPharm and biotechnology company Acuitases Therapeutics announced that they are expanding their strategic partnership and are prepared to conduct technology transfers as well as CGMP manufacturing for clients licensing Acuitas' LNP (Lipid nanoparticle) formulations for mRNA-based therapeutics and vaccines.

Pharmaceutical CMO Market Leaders

1. Catalent Inc.

2. Recipharm AB

3. Jubilant Biosys Ltd.(Jubilant Pharmova Ltd)

4. Patheon Inc. (Thermo Fisher Scientific Inc.)

5. Boehringer Ingelheim Group

*Disclaimer: Major Players sorted in no particular order